Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Abidi

Showing results (81-90 of 231) with videos related to

Pageof 24
Sort By:
International Journal of Molecular Sciences|January 10, 2026
Cannabinoid Signaling and Autophagy in Oral Disease: Molecular Mechanisms and Therapeutic ImplicationsUndral Munkhsaikhan, Md Ataur Rahman, Alivia Shasteen, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 13, 2025
Unraveling the oral microbiome's role in Alzheimer's disease: From pathophysiology to therapeutic potentialGilliana Rozenblum, Karima Ait-Aissa, Gadeer Zahran, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaMuthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
The Journal of Contemporary Dental Practice|March 28, 2022
Socket-shield Technique: A Systematic (Scoping) Review of Case Series and Case ReportsFuad A Al-Sanabani, Nazim H Abidi, Manea M Al-Ahmari, et al.
Bone Marrow Transplantation|April 12, 2005
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literatureR B Ibrahim, E Peres, R Dansey, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 18, 2013
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaDivaya Bhutani, Jeffrey Zonder, Jason Valent, et al.
Journal of Clinical Apheresis|April 5, 2014
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplantMuthu Veeraputhiran, Tania Jain, Simon Cronin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2012
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trialMuneer H Abidi, Rishi Agarwal, Lois Ayash, et al.
Animals : an Open Access Journal From MDPI|December 11, 2025
The Role of Short-Chain Fatty Acids (SCFAs) in Colic and Anti-Inflammatory Pathways in HorsesNathan Schank, Ashley Cottone, Michelle Wulf, et al.
Pageof 24

Showing results (81-90 of 231) with videos related to

Sort By:
Pageof 24
International Journal of Molecular Sciences|January 10, 2026
Cannabinoid Signaling and Autophagy in Oral Disease: Molecular Mechanisms and Therapeutic ImplicationsUndral Munkhsaikhan, Md Ataur Rahman, Alivia Shasteen, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 13, 2025
Unraveling the oral microbiome's role in Alzheimer's disease: From pathophysiology to therapeutic potentialGilliana Rozenblum, Karima Ait-Aissa, Gadeer Zahran, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaMuthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
The Journal of Contemporary Dental Practice|March 28, 2022
Socket-shield Technique: A Systematic (Scoping) Review of Case Series and Case ReportsFuad A Al-Sanabani, Nazim H Abidi, Manea M Al-Ahmari, et al.
Bone Marrow Transplantation|April 12, 2005
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literatureR B Ibrahim, E Peres, R Dansey, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 18, 2013
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaDivaya Bhutani, Jeffrey Zonder, Jason Valent, et al.
Journal of Clinical Apheresis|April 5, 2014
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplantMuthu Veeraputhiran, Tania Jain, Simon Cronin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2012
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trialMuneer H Abidi, Rishi Agarwal, Lois Ayash, et al.
Animals : an Open Access Journal From MDPI|December 11, 2025
The Role of Short-Chain Fatty Acids (SCFAs) in Colic and Anti-Inflammatory Pathways in HorsesNathan Schank, Ashley Cottone, Michelle Wulf, et al.
Pageof 24